Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by SRS Capital Advisors Inc.

SRS Capital Advisors Inc. boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,246 shares of the medical equipment provider’s stock after buying an additional 393 shares during the period. SRS Capital Advisors Inc.’s holdings in Intuitive Surgical were worth $1,444,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Chicago Capital LLC boosted its stake in Intuitive Surgical by 1.0% during the second quarter. Chicago Capital LLC now owns 29,244 shares of the medical equipment provider’s stock worth $13,009,000 after buying an additional 294 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC boosted its stake in Intuitive Surgical by 3.4% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after buying an additional 23 shares during the last quarter. Cullen Frost Bankers Inc. boosted its stake in Intuitive Surgical by 35.7% during the second quarter. Cullen Frost Bankers Inc. now owns 71,305 shares of the medical equipment provider’s stock worth $31,720,000 after buying an additional 18,745 shares during the last quarter. Patron Partners LLC lifted its stake in shares of Intuitive Surgical by 3.9% in the 2nd quarter. Patron Partners LLC now owns 1,845 shares of the medical equipment provider’s stock valued at $821,000 after purchasing an additional 69 shares during the last quarter. Finally, Sivia Capital Partners LLC lifted its stake in shares of Intuitive Surgical by 6.1% in the 2nd quarter. Sivia Capital Partners LLC now owns 781 shares of the medical equipment provider’s stock valued at $347,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Citigroup upped their price target on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Evercore ISI decreased their price target on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. Stifel Nicolaus upped their price target on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Piper Sandler upped their price target on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Finally, BTIG Research upped their price target on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Stock Down 1.0 %

NASDAQ ISRG traded down $4.87 during trading hours on Friday, hitting $471.82. 1,700,169 shares of the company were exchanged, compared to its average volume of 1,518,588. The company has a 50 day moving average of $458.74 and a two-hundred day moving average of $417.98. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $493.97. The firm has a market cap of $167.35 billion, a price-to-earnings ratio of 85.17, a PEG ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the business earned $1.18 EPS. Intuitive Surgical’s revenue was up 14.5% on a year-over-year basis. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Activity

In other news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,655,048.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,656 shares of company stock worth $24,700,644. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.